News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
352,782 Results
Type
Article (21768)
Company Profile (110)
Press Release (330895)
Multimedia
Podcasts (133)
Webinars (20)
Section
Business (106276)
Career Advice (905)
Deals (18800)
Drug Delivery (129)
Drug Development (51334)
Employer Resources (80)
FDA (7947)
Job Trends (7882)
News (187712)
Policy (17537)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (4)
Academia (761)
Accelerated approval (35)
ADA (26)
Adcomms (25)
Allergies (120)
Alliances (28004)
ALS (122)
Alzheimer's disease (894)
Antibody-drug conjugate (ADC) (323)
Approvals (8267)
Artificial intelligence (390)
ASCO (174)
Autoimmune disease (184)
Automation (27)
Bankruptcy (181)
Best Places to Work (5565)
BIO (37)
BIOSECURE Act (14)
Biosimilars (213)
Biotechnology (53)
Bladder cancer (91)
Brain cancer (46)
Breast cancer (335)
Cancer (3019)
Cardiovascular disease (310)
Career advice (762)
Career pathing (31)
CAR-T (140)
CDC (21)
Cell therapy (377)
Cervical cancer (22)
Clinical research (46109)
Collaboration (1326)
Commercialization (1)
Company closure (2)
Compensation (489)
Complete response letters (72)
COVID-19 (1200)
CRISPR (64)
C-suite (805)
Cystic fibrosis (96)
Data (4608)
Decentralized trials (3)
Denatured (30)
Depression (104)
Dermatology (55)
Diabetes (327)
Diagnostics (1986)
Digital health (25)
Diversity (9)
Diversity, equity & inclusion (22)
Drug discovery (257)
Drug pricing (220)
Drug shortages (36)
Duchenne muscular dystrophy (185)
Earnings (41988)
Editorial (56)
Employer branding (10)
Employer resources (80)
Events (52480)
Executive appointments (731)
FDA (10004)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (8)
Frontotemporal dementia (10)
Funding (867)
Gene editing (116)
Generative AI (46)
Gene therapy (339)
GLP-1 (938)
Government (2089)
Grass and pollen (4)
Guidances (219)
Healthcare (6037)
Hematology (92)
HIV (45)
Huntington's disease (35)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (86)
Immunology and inflammation (222)
Immuno-oncology (60)
Indications (147)
Infectious disease (1390)
Inflammatory bowel disease (150)
Inflation Reduction Act (12)
Influenza (61)
Intellectual property (173)
Interviews (124)
IPO (7462)
IRA (54)
Job creations (2452)
Job search strategy (660)
JPM (55)
Kidney cancer (15)
Labor market (83)
Layoffs (363)
Leadership (35)
Legal (4164)
Liver cancer (41)
Longevity (15)
Lung cancer (425)
Lymphoma (265)
Machine learning (25)
Management (31)
Manufacturing (756)
Marketing (2)
MASH (140)
Medical affairs (1)
Medical device (2028)
Medtech (2051)
Mergers & acquisitions (11990)
Metabolic disorders (1146)
mRNA (114)
Multiple sclerosis (127)
NASH (21)
Neurodegenerative disease (229)
Neuropsychiatric disorders (93)
Neuroscience (1866)
Neurotech (1)
NextGen: Class of 2026 (2379)
Non-profit (932)
Now hiring (61)
Obesity (660)
Opinion (252)
Ovarian cancer (102)
Pain (189)
Pancreatic cancer (142)
Parkinson's disease (226)
Partnered (20)
Patents (365)
Patient recruitment (413)
Peanut (22)
People (35174)
Pharmaceutical (55)
Pharmacy benefit managers (38)
Phase 1 (14560)
Phase 2 (19451)
Phase 3 (15620)
Pipeline (5463)
Policy (267)
Postmarket research (1628)
Preclinical (5087)
Press Release (29)
Prostate cancer (173)
Psychedelics (38)
Radiopharmaceuticals (224)
Rare diseases (752)
Real estate (3218)
Recruiting (35)
Regulatory (14517)
Reports (27)
Research institute (856)
Resumes & cover letters (142)
Rett syndrome (14)
RNA editing (18)
RSV (51)
Schizophrenia (149)
Series A (168)
Series B (107)
Service/supplier (6)
Sickle cell disease (82)
Special edition (25)
Spinal muscular atrophy (126)
Sponsored (20)
Startups (2067)
State (2)
Stomach cancer (13)
Supply chain (97)
Tariffs (97)
The Weekly (100)
Vaccines (488)
Venture capital (94)
Weight loss (468)
Women's health (68)
Worklife (10)
Date
Today (3)
Last 7 days (255)
Last 30 days (1130)
Last 365 days (15234)
2026 (8191)
2025 (15485)
2024 (17641)
2023 (19645)
2022 (25916)
2021 (26709)
2020 (24907)
2019 (20106)
2018 (15625)
2017 (17287)
2016 (16223)
2015 (18812)
2014 (14804)
2013 (12562)
2012 (13488)
2011 (13824)
2010 (12741)
Location
Africa (423)
Alabama (48)
Alaska (1)
Arizona (105)
Arkansas (9)
Asia (26487)
Australia (3419)
California (6017)
Canada (2224)
China (1037)
Colorado (249)
Connecticut (249)
Delaware (245)
Europe (54720)
Florida (1065)
Georgia (121)
Hawaii (2)
Idaho (20)
Illinois (587)
India (78)
Indiana (370)
Iowa (5)
Japan (463)
Kansas (92)
Kentucky (34)
Louisiana (11)
Maine (4)
Maryland (723)
Massachusetts (4804)
Michigan (77)
Minnesota (302)
Mississippi (3)
Missouri (49)
Montana (13)
Nebraska (15)
Nevada (41)
New Hampshire (11)
New Jersey (2316)
New Mexico (21)
New York (1652)
North Carolina (968)
North Dakota (2)
Northern California (2912)
Ohio (163)
Oklahoma (8)
Oregon (23)
Pennsylvania (1307)
Puerto Rico (28)
Rhode Island (29)
South America (619)
South Carolina (13)
South Dakota (1)
Southern California (2584)
Tennessee (86)
Texas (828)
United States (22644)
Utah (110)
Vermont (1)
Virginia (234)
Washington D.C. (60)
Washington State (474)
West Virginia (1)
Wisconsin (65)
Wyoming (1)
352,782 Results for "rocket pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Gene therapy
Rocket’s Gene Therapy Wins FDA Greenlight, Clearing Way for Future Products
While the accelerated approval unlocks only a small market opportunity for Rocket Pharmaceuticals, it will give the biotech a chance to prepare for future product launches, according to Jefferies.
March 27, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Rocket Pharmaceuticals to Participate in Upcoming June 2026 Investor Conferences
May 28, 2026
·
4 min read
Press Releases
Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
June 12, 2026
·
4 min read
Press Releases
Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher
April 28, 2026
·
6 min read
Press Releases
Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress
May 8, 2026
·
15 min read
China
New biotech group rises to fuel American rockets in China ‘space race’
Members of the American Biotech Innovation Alliance (ABIA) want to build a national biotech strategy—just like China did years ago.
June 10, 2026
·
3 min read
·
Annalee Armstrong
Gene therapy
Rocket Aborts FDA Filing for Rare Blood Disease Gene Therapy
Rocket Pharmaceuticals’ strategic realignment initiative in July pulled funding from fanca-cel, which the biotech was developing for Fanconi anemia.
October 6, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Rocket Pharmaceuticals to Participate in Upcoming March 2026 Investor Conferences
February 23, 2026
·
5 min read
Business
Deep dive: Pharma CEO compensation report
Who is the highest paid CEO in all of pharma? In this special edition,
BioSpace
examines top paid CEOs and their pay packages.
June 30, 2026
·
1 min read
·
Annalee Armstrong
Press Releases
Guangzhou Lupeng/Newave Pharmaceutical Inc. Enrolled the First Patient in the Global Phase 3 ROCKET-CLL Trial Evaluating Rocbrutinib (LP-168) vs. Pirtobrutinib in R/R CLL/SLL
Head-to-Head Study Highlights Rocbrutinib as the World’s First Fourth-Generation Dual Covalent and Non-Covalent BTK Inhibitor Designed to Overcome Resistance Mutations
May 21, 2026
·
1 min read
1 of 35,279
Next
